Clinical Trial Update: A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating valemetostat (DS-3201b) in combination with darolutamide for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)
• valemetostat (valemetostat)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: RECRUITING